NSCLC. Harmonization study 1. Lung cancer and other malignancies -PD-L1 assay, QuIP EQA

Similar documents
Lung cancer PD-L1 testing clinical impact

Vernieuwing en diagnostiek bij NSCLC: Immunotherapy: PD-L1 analyse: waar staan we

Quality control of PD-L1 in NSCLC - Results of two German ring trials Dr. Andreas Scheel University Hospital Cologne

Predictive Biomarkers for Pembrolizumab. Eric H. Rubin, M.D.

Role of the Pathologist in Guiding Immuno-oncological Therapies. Scott Rodig MD, PhD

Review of NEO Testing Platforms. Lawrence M. Weiss, MD Medical Director, Aliso Viejo

ICLIO National Conference

Predictive markers for treatment with Immune checkpoint inhibitors - PD-L1 et al -

PD-L1 Testing German Experience. P. Schirmacher for QuIP

Emerging Tissue and Serum Markers

Agilent companion diagnostics for cancer immunotherapy

Biomarkers for Cancer Immunotherapy Debate

Policy. Medical Policy Manual Approved Revised: Do Not Implement Until 3/2/19. Nivolumab (Intravenous)

Supplementary Online Content

Immunotherapy in NSCLC Pathologist role

The Role of Immuno-Oncology Biomarkers in Lung Cancer

Policy. Medical Policy Manual Approved Revised: Do Not Implement until 6/30/2019. Nivolumab

Histology independent indications in Oncology

PD-L1 and Immunotherapy of GI cancers: What do you need to know

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

Assessment Run C3 2018

Keytruda. Keytruda (pembrolizumab) Description

Optimal Evaluation of Programmed Death Ligand-1 on Tumor Cells Versus Immune Cells Requires Different Detection Methods

Immuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017

Innovation, Uncertainty and Reimbursement Processes in Precision Medicine: The Case of PD-L1

(generic name: ipilimumab) Injection 50 mg ( Yervoy ), a human anti-human CTLA-4 monoclonal. August 21, 2018

Keytruda. Keytruda (pembrolizumab) Description

Emerging biomarkers for immunotherapy in lung cancer

Assessment Run C1 2017

Immunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University

Clinical Policy: Nivolumab (Opdivo) Reference Number: ERX.SPA.302 Effective Date:

Professor Mark Bower Chelsea and Westminster Hospital, London

I farmaci immunoterapici. Stefano Fogli UO Farmacologia Clinica e Farmacogenetica Dipartimento di Medicina Clinica e Sperimentale Università di Pisa

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment

Checkpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015

Immunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care

Updates in Immunotherapy for Urothelial Carcinoma

Lung Cancer Immunotherapy

Post-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy

Keytruda. Keytruda (pembrolizumab) Description

PD-L1 Expression, Role, and Significance in Lung Pathology. Ross A Miller, MD FACP FASCP

Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy

Strengths and Weaknesses of PD-L1 testing: Pathology perspective

Immunotherapie: algemene principes

MICROSCOPY PREDICTIVE PROFILING

Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates

Advances in Pathology and molecular biology of lung cancer. Lukas Bubendorf Pathologie

Current experience in immunotherapy for metastatic renal cell carcinoma

El contexto molecular de la sobreexpresión de PD-L1 Esther Conde Gallego, MD, PhD

Lung Cancer Update on Pathology Zhaolin Xu, MD, FRCPC, FCAP

Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer

Immuno-Oncology Applications

Emerging Targets in Immunotherapy

Keytruda. Keytruda (pembrolizumab) Description

First Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor

News from ASCO. Niven Mehra, Medical Oncologist. Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital

Out of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.

Cancer Immunotherapy Patient Forum. for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015

The Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb

ENDOCRINE ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT IMMUNOTHERAPY

Challenges in Distinguishing Clinical Signals to Support Development Decisions: Case Studies

CANCER IMMUNOTHERAPY Presented by John A Keech Jr DO MultiCare Regional Cancer Center

La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD

PD-L1 Analyte Control DR

SUPPLEMENTARY INFORMATION

Corporate presentatie Maastricht UMC+ (titel presentatie)

TITLE: UK NEQAS ICC & ISH Pre-Pilot Meeting for PD-L1. Immunohistochemistry in Non-Small Cell Lung Carcinoma

New Oncology Drugs: Nadeem Ikhlaque, M.D Subtitle Would Go Here

Enterprise Interest Lecture 9º Personalized Healthcare in Oncology sponsored by Roche, Lisbon 2017 Bladder Diagnostic Advisory Board Invitation

Lights and sheds of early approval of new drugs in clinical routine. Carmen Criscitiello, MD, PhD European Institute of Oncology Milan, Italy

Immune checkpoint inhibitors in NSCLC

HER2 status assessment in breast cancer. Marc van de Vijver Academic Medical Centre (AMC), Amsterdam

QIAGEN's Growing Immuno-Oncology Testing Portfolio

Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker

Overview of Biomarker Development for Immune PD-1/L1 Checkpoint Blockade

See Important Reminder at the end of this policy for important regulatory and legal information.

Merck Oncology Overview ASCO 2017

Role of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney

Merck Oncology Overview ASCO 2017

Immunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States

Merck Oncology Overview. The Development of MSI-H Cancer Therapy. Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 2017

O DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal. Gabriela Sousa Oncologia Médica IPO Coimbra

Patient Selection: The Search for Immunotherapy Biomarkers

Opdivo. Opdivo (nivolumab) Description

Companion & Complementary Diagnostics: Clinical and Regulatory Perspectives

Breast cancer: Antibody selection, protocol optimzation controls and EQA

We re Reaching Ludicrous Speed: New Immunotherapy Oncology Medications

VENTANA PD-L1 (SP142) Assay Guiding immunotherapy in NSCLC

Is Immune Therapy the Holy Grail in Metastatic Kidney Cancer?

Citi Global Healthcare Conference

ASCO 2014 Highlights*

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid

Diagnostic & Predictive Immunohistochemistry in Lung Carcinomas

THE SEARCH FOR BIOMARKERS IN BLADDER CANCER

Assessment Run GATA3

Releasing the Brakes on Tumor Immunity: Immune Checkpoint Blockade Strategies

Biomarcatori per la immunoterapia: cosa e come cercare Paolo Graziano

Transcription:

Lung cancer and other malignancies -PD-L1 assay, QuIP EQA Korinna Jöhrens Institute for pathology Carl Gustav Cars Universitätsklinikum Dresden, Germany Medical consultant QuIP 11.05.2018 NSCLC Harmonization study 1 9 German institutes for pathology NSCLC slides from tumor-resections stainings in reference laboratories DAKO/Ventana evaluation according to the Cologne Scores

Cologne Score Scheel et.al: Mod Pathol. 2016 Oct;29(10):1165-72 Results I Good interobserver concordance for tumor cells (light s kappa 0.6-0.8) poor interobserver concordance for immune cells Results II membranous staining: complete/incomplete cytoplasmatic staining is not counted different assays do not show identical staining patterns different antibodies stained on the same platform showed similar results

Results III 28-8, 22C3, SP263 showed similar patterns SP142 showed different pattern: linear, sometimes granular 28-8 und 22C3 showed similar proportions SP263 stained higher numbers of tumor cells SP142 stained lower numbers of tumor cells Scheel et.al: Mod Pathol. 2016 Oct;29(10): 1165-72 Harmonization study 2 # Participant Benchmark 01 Cologne Büttner/Scheel Ventana Ultra & Dako Autostainer Link 48 02 Cassel (PNH/Targos) Rüschoff/Jasani Göttingen Schildhaus Berlin Dietel/Jöhrens Munic Kirchner/Reu Dako Autostainer Link 48 Ventana Ultra & XT Dako Autostainer Link 48 Munic Weichert Ventana Ultra, Dako Autostainer Plus 22C3 03 04 05 06 07 Ventana Ultra & XT Dako Autostainer Link 48 Ventana Ultra & XT Ventana Ultra Heidelberg Schirmacher/ Ventana Ultra Lasitschka XX Dresden Baretton Ventana SP142 SP263 In house X (22C3) X (28-8) X (28-8) Hamburg Tiemann/Heukamp 08 Dako 28-8 Ventana Ultra & XT Scheel et al. Histopathology. 2018 Feb;72(3):449-459 X (22C3) (E1L3N) X (28-8) X (28-8) (22C3) X (22C3) X (SP263?) X (??)

Results stainings are reproducible similar results in different institutions LDT stainings are similar when carefully validated Scheel et al. Histopathology. 2018 Feb;72(3):449-459 ring trial PD-L1 NSCLC: case selection criteria Case selection : equal distribution of the cases in the following 3 different categories: category 1: < 1%: 3 cases category 2: 1% < 49%: 4 cases category 3: 50%: 3 cases tumor tissue type: resections ring trial PD-L1 NSCLC: structure Internal ring trial: 1. part: lead-institutes (3) 2. part: panel institutes (4) Open ring trial : 10 cases 2 slides per cases = 20 slides for the participants

assessment criteria 2 points were given for each case poor staining results or poor intensity interpretation: 2 points deduction technical problems 1 point detraction Passed the test: 18 points 2. Ring trial PD-L1 NSCLC: chosen methods free choice of methods lead- and panel institutes Dako, Leica, Ventana SP263, SP142, 28-8, 22C3, E1L3N Der Pathologe, in Vorbereitung RT1/2016 and RT2/2017:PD-L1- NSCLC Participants: 1. 83 2. 94 with success: 1. 60 2. 72 failed: 1. 23 2. 22 1. 72% 2. 77%

Antibodies used by participants RT1 and RT2 AK RT1 88% RT2 E1L3N 22/25 16/21 76% 28-8 13/20 65% 6/11 22C3 9/13 69% 14/21 55% 67% QR1 4/6 5/11 46% SP263 2/5 CAL10 3/4 ZR3 2/3 5/4 SP142 2/2 0 3/4 10/13 77% Positive controls Placenta positive controls

LDT calibration with cell-lines Ring trial PD-L1 NSCLC: interpretation of results Free choice of methods learning success: 11/15 of the participants, who failed the first ring trial, passed the second (73,3%). Der Pathologe, in Vorbereitung Immune therapy with checkpoint-inhibitors - overview - Melanoma NSCLC RCC UC SCCHN chl MCC MSI GC/GEJ Ipilimumab (anti-ctla-4) Nivolumab (anti-pd-1) Pembrolizumab (anti-pd-1) Atezolizumab (anti-pd-l1) Durvalumab (anti-pd-l1) Avelumab (anti-pd-l1) 1st 2nd 1st 2nd 2nd 1st 2nd 2nd >3rd 2nd >1st >2nd + + + 1 + 1 + + + + + 6 + (CRC) + + + 3,7 + 2 + 5 + + + 4,6 + + 8 + + 5 + + + + + 1 = also in combination with Ipilimumab 2 = only for PD-L1 positive tumors (TPS 1%) 3 = only for PD-L1 positive tumors (TPS 50%) 4 = FDA: 4. line or refractory (also pediatric pat.) 5 = if Cisplatin is inapplicable 6 = EMA: after BV-therapy+ auto-szt; Pembro additionally after BV-therapy, if auto-sct is not possible 7 = in combination with Pemetreed und Carboplatin in non-squamous NSCLC 8 = only for PD-L1 positive tumors (CPS 1) Until now only FDA

PD-L1-epression is variable between different entities Entities PD-L1 epression malignant melanoma 40-100 NSCLC 35-95 naso-pharyn carcinoma 68-100 glioblastoma, glioma 100 colo-rectal-carcinoma (Adeno) 53 hepatocellular carcinoma 45-93 urothelial carcinoma 28-100 multiple myeloma 93 Ovarian carcinoma 33-80 gastric carcinoma 42 esophageal carcinoma 42 pancreatic carcinoma 39 renal cell carcinoma 15-24 lymphoma 17-94 leukemia 11-42 BMS PD-L1 epression may vary depending on the previous therapies 1 12 Agent Cell Type Effect on PD-L1 Epression Radiation therapy 1-3 Colorectal, breast, melanoma Up-regulated* Cisplatin Hepatoma 4 Up-regulated* HNSCC 5 Paclitael Breast6, Colorectal, hepatocellular carcinoma7 Up-regulated* Etoposide6 Breast Up-regulated* Oaliplatin 8 Plasmacytoid dendritic cells Up-regulated* Doorubicin9 Breast Down-regulated* Gefitinib NSCLC Down-regulated* 10 Up-regulated 11 Sunitinib / Pazopanib12 Metastatic RCC Down-regulated * PD-L1 epression determined by flow cytometry. PD-L1 epression determined by qrt-pcr or transcriptomeic profiling. PD-L1 epression determined by western blots. PD-L1 epression determined by IHC. In tumors resistant to radiation + anti-ctla-4. HNSCC = head and neck squamous cell carcinoma; IHC = immunohistochemistry; NSCLC = non-small cell lung cancer; PD-L1 = programmed death ligand 1; RCC = renal cell carcinoma. 1. Dovedi SJ et al. Cancer Res. 2014; 74(19): 5458-5468 2. Deng L et al. J Clin Invest. 2014; 124(2): 687-695 3. Twyman-Saint Victor C et al. Nature. 2015; 520(7547): 373-377 4. Qin X et al. Cell Mol Biol. 2010; 56 Suppl: OL1366-72 5. Qiao P et al. Poster presentation at AACR 2014. 3750 6. Zhang P et al. Mol Immunol. 2008; 45(5):1470-1476 7. Gong W et al. J Chemother. 2011; 23(5): 295-299 8. Tel J et al. Cancer Immunol Immunother. 2012; 61(7): 1101-1111 9. Ghebeh H et al. Breast Cancer Res. 2010; 12(4): R48 10. Lin K et al. Biochem Biophys Res Commun. 2015; 463(1-2): 95-101 11. Omori S et al. Abstract presented at ASCO 2015 Annual Meeting. e22118 12. Sharpe K et al. Clin Cancer Res. 2013; 19(24): 6924-6934. BMS PD-L1-Testing ASSAY Characteristica Nivolumab Nivolumab Pembrolizumab Pembrolizumab Atezolizumab Durvalumab company Bristol-Myers Squibb MSD Roche AstraZeneca Target of the therapeutic PD-1 (etracellular Antibody domaine) PD-1 (etracellular domaine) PD-1 (etracellular domaine) PD-1 (etracellular domaine) PD-L1 (intracellular domaine) PD-L1 PD-1 (etracellular domaine) PD-L1-POSITIVITY IHC-Assay producer Dako Ventana Dako Ventana Ventana Ventana IHC-antibody-clone 28-8 (rabbit) SP263 (rabbit) 22C3 (mouse) SP263 (rabbit) SP142 (rabbit) SP263 (rabbit) Evaluation PD-L1-epression and stroma and Stroma Tumor-infiltrtating immune cells (TICs) & Cut-off innsclc 1%, 5%, 10% TC 1%, 5%, 10% TC 1%, 50% TC (or every tumor-stroma-cell) 1%, 50% TC (or every tumor-stromacell) IHC 2+ 5 % to 10 % TZ or TIC or IHC 3+ 10% TC or TIC 25% TC Depending on the therapeutic antibodies different PD-L1-Assays with different clones and specific evaluation algorithm regarding IHC-stainings are developed. modified from Aaron R. Hansen & Lillian L. Siu, PD-L1 Testing in Cancer, Challenges in Companion Diagnostic Development: JAMA Oncology January 2016 Volume 2, Number 1 BMS

Harmonization study urothelial carcinoma Design PLACU-Study Analytical comparison of the percentage of PD-L1 stained immune cells (per tumor area) and PD-L1 stained tumor cells in 30 patients with advanced urothelial carcinoma. For comparison, the clinical trials validated assays Ventana SP142, Ventana SP263, Dako 28-8 and Dako 22C3 were used. All 5 evaluators were trained on the evaluation of immune cells (eminating on the assay SP142). U. Sommer, institute for pathology,carl Gustav Carus, Universitätsklinikum Dresden Harmonization study renal cell carcinoma Roche PAIR-Studie Analytical comparison of the percentage of PD-L1 stained immune cells (per tumor area) and PD- L1 stained tumor cells in 30 patients with advanced clear cell renal cell carcinoma. Staining with the clinically validated PD-L1 assays Ventana SP142 and SP263, Dako 28-8 and 22C3 (each according to manufacturer's protocols). U. Sommer, institute for pathology,carl Gustav Carus, Universitätsklinikum Dresden Harmonization study urothelial-, gastric- HNSCCcarcinoma MSD 6 German institutes for pathology In progress

Questions A positive PD-L1 staining is localized in/at the A) nucleus B) cytoplasm C) membrane 2. SP142 stained A) a lower number of tumor cells B) a higher number of tumor cells C) similar to SP263 3. Which tissue should be used as a positive control for PD-L1: A) placenta B) tonsil C) classical Hodgkin lymphoma